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A recent advance that has revitalized toxi-
cology studies in the past couple of decades 
is Frontiers in Genetics “toxicogenomics,” 
the study of the effects of environmen-
tal toxins on global changes within a cell 
or tissue as related to genomic variables. 
“Transcriptional toxicogenomics” is the 
study of global gene expression patterns 
after administering a toxin. Similarly, 
“toxicoproteomics” is the study of global 
changes in protein levels or post-trans-
lational modifications; while “toxicome-
tabolomics” is the study of global changes 
in metabolite levels after administering a 
toxin. A new field called “toxicoepigenom-
ics” or more simply, the “epigenetics of 
toxicology,” is the study of global epigenetic 
changes in a cell that are caused by exposure 
of a cell, tissue, or organism to a toxin or 
drug. Frontiers in Toxicogenomics provides a 
format for presenting cutting-edge reviews 
and studies in the frontiers of all branches 
of toxicogenomics.
One type of study within the area of 
transcriptional toxicogenomics called 
“genetical genomics” or “genetics of gene 
expression,” is the combination of quan-
titative trait-locus (QTL) and whole-
genome expression analyses (Brem et al., 
2002; Broman, 2005). In genetical genom-
ics, the investigator treats the expression of 
each of the ∼20,000 genes in an organism 
as a quantitative trait and identifies cis-
expression QTL (eQTL) in cis-regulatory 
sequences and trans-eQTL in trans-acting 
factors that regulate expression of co-regu-
lated genes in specific pathways. Genetical 
toxicogenomics adds a new dimension to 
genetical genomics by studying the effects 
of an environmental toxin on global gene 
expression patterns (Ruden et al., 2009). 
Such studies are theoretically very power-
ful because they not only tell which genes 
are induced in a particular tissue (such as 
a brain region) by the toxin, but they also 
allow the identification of trans-acting 
factors and cis-acting sequences that are 
regulated by the toxin. Toxicogenetical 
genomic studies in mice have the advan-
tage that thousands of recombinant inbred 
lines have recently been generated in a 
collaborative cross amongst eight differ-
ent wild type strains of mice (Churchill 
et al., 2004). Rats are sometimes preferred 
models for toxicological screens because 
they have much larger organs than mice, 
allowing for easier gene and protein 
expression analyses because much more 
material can be obtained compared with 
mice. Recombinant inbred lines have also 
been developed in rats, and some labora-
tories have conducted genetical genomics 
and genetical toxicogenomics analyses in 
rats, especially in the rat brain.
The transcriptional toxicogenomic stud-
ies have mostly been done with recombinant 
inbred lines, such as in mice, C. elegans, 
and Drosophila, and utilized gene expres-
sion microarrays. However, next-generation 
sequencing technologies allow new types of 
transcriptional toxicogenomic studies to 
be conducted. For example, “speed QTL” 
analyses can be done by selecting a large 
population of model organisms for a par-
ticular trait, such as lifespan after feeding 
a toxin, for several generations and then 
sequencing the genome of the long-living 
descendents (Lai et al., 2007). The single 
nucleotide polymorphisms (SNPs) that are 
enriched in the long-living descendents are 
located in candidate toxin-survival genes 
which can be studied in follow up genetic 
and biochemical studies. Third generation 
sequencing technologies will soon make 
the “$1000 genome” a reality and will not 
only allow “personalized medicine,” which 
is using a person’s genome sequence to 
optimize a drug regimen to treat a  disease 
(Ruden, 2007), but also “personalized 
 toxicogenomics” which uses this genome 
information to determine a person’s sus-
ceptibility to an environmental toxin.
Toxicoproteomics and toxicometabo-
limics are new areas that utilize state-
of-the-art mass spectrometry and other 
sensitive assay systems that can quantify 
protein, peptide, and metabolic levels in 
a population of model organisms. Instead 
of gene expression being the quantitative 
trait, as in transcriptional toxicogenom-
ics, protein, and metabolite levels can be 
used as quantitative traits. In this manner, 
protein QTL (pQTL) and metabolite-QTL 
(mQTL) can be identified in both cis- 
and trans-genes that regulate the levels 
of molecules.
Toxicoepigenomics is the study of global 
epigenomic changes, such as DNA meth-
ylation changes, histone modifications, 
or microRNA changes, that are caused by 
exposure to toxins. In this manner, epi-
genetic-QTL (epiQTL) can be identified 
that identify cis- and trans-regulatory ele-
ments and factors that alter the epigenome 
in response to a toxin. It is known for 
instance that prenatal lead exposure causes 
hypomethylation of repeats in humans. It 
would be interesting to study global meth-
ylation patterns after exposure to lead and 
other toxins in large populations.
In conclusion, toxicogenomics is an 
exciting new field that has revitalized toxi-
cology research. No longer need toxicolo-
gists study only LD50 values (lethal dose 
that kills 50% of the population) and use 
death alone as a toxicology endpoint. Now 
toxicologists can perform studies with much 
more subtle endpoints, such as gene expres-
sion, protein or metabolite levels, and epig-
enomic changes. Frontiers in Toxicogenomics 
provides a format for present research and 
reviews in this exciting new field.
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